Pharmaceutical Economy In China Sees Steady Growth
This article was originally published in PharmAsia News
Executive SummaryAccording to recent statistics, total purchases of the top seven medical products in China were RMB 192.6 billion from January to June, an increase of 10.74 percent compared to the same period last year. Among them, pharmaceutical products accounted for RMB 147.2 billion, up 11.85 percent; and medical devices, in the amount of RMB 2.4 billion, increased 1.27 percent. The total sales were RMB 213.7 billion, 11.66 percent more than the same period last year. The areas that took the lead in sales were Shanghai, Beijing, Zhejiang, Guangdong, Jiangsu and Anhui. Total sales in these regions account for 62 percent of China's total sales. (Click here for more - Chinese lanugage)
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.